Immune Cell Assays

Immuno-oncology has emerged as one of the most promising treatments for cancer, either alone or in combination with other therapies. These therapies activate the immune system to destroy cancerous cells either by targeting stimulatory receptors or by inhibiting key checkpoints in the T-cell immune response. With growing interest and applications of clinical trial testing of these checkpoint inhibitors, we have built an expert team to focus on the critical interactions between the immune system and immuno-oncology drugs such as, PD-1 and PD-L1 inhibitors.

In order to accurately characterize immune cell interactions during the development process, our team is available to offer the following assays:

  • Activation
  • Proliferation
  • Cytokine Production
  • Regulation/Suppression
  • Cell death
  • ADCC
  • ACDP

More From Less

BioOutsource employs the iQue Screener PLUS to examine multiple readouts within a single assay, reducing the time and requirement for sample. Our scientific team works to optimize your process and accurately interpret critical data. Combining phenotypic and functional readouts in a single measurement, assays can be designed to suit your molecule.

Contact our experts now to discuss your requirements for your molecule.

BioOutsource Immune Cell Assays

 

Sign-up to our newsletter to be the first to hear about our new services & offers

Sign-up to our newsletter to be the first to hear about our new services & offers

Enter your email address to subscribe to our newsletter which provides information about our services. By subscribing, you are agreeing to the processing of your personal information for this purpose as set out in our privacy policy